Articles with public access mandates - Andries M BergmanLearn more
Not available anywhere: 2
Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis
S Stelloo, E Nevedomskaya, Y Kim, L Hoekman, OB Bleijerveld, T Mirza, ...
Oncogene 37 (3), 313-322, 2018
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours
MAC Vermunt, LT van der Heijden, JJMA Hendrikx, AH Schinkel, ...
Cancer Chemotherapy and Pharmacology 87, 855-869, 2021
Mandates: Netherlands Organisation for Health Research and Development
Available somewhere: 45
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a …
ED Kwon, CG Drake, HI Scher, K Fizazi, A Bossi, AJM Van den Eertwegh, ...
The lancet oncology 15 (7), 700-712, 2014
Mandates: US National Institutes of Health
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
MM Pomerantz, X Qiu, Y Zhu, DY Takeda, W Pan, SC Baca, A Gusev, ...
Nature genetics 52 (8), 790-799, 2020
Mandates: US Department of Defense, US National Institutes of Health, Netherlands …
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
LF van Dessel, J van Riet, M Smits, Y Zhu, P Hamberg, ...
Nature communications 10 (1), 5251, 2019
Mandates: US National Institutes of Health, Dutch Cancer Society
Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer
KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ...
Journal of Clinical Oncology 41 (18), 3339-3351, 2023
Mandates: US National Institutes of Health
Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of …
K Fizazi, CG Drake, TM Beer, ED Kwon, HI Scher, WR Gerritsen, A Bossi, ...
European urology 78 (6), 822-830, 2020
Mandates: US National Institutes of Health
Integrative epigenetic taxonomy of primary prostate cancer
S Stelloo, E Nevedomskaya, Y Kim, K Schuurman, E Valle-Encinas, ...
Nature communications 9 (1), 4900, 2018
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
CHD1 loss alters AR binding at lineage-specific enhancers and modulates distinct transcriptional programs to drive prostate tumorigenesis
MA Augello, D Liu, LD Deonarine, BD Robinson, D Huang, S Stelloo, ...
Cancer Cell 35 (4), 603-617. e8, 2019
Mandates: US Department of Defense, US National Institutes of Health, Dutch Cancer …
An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer
A Davies, S Nouruzi, D Ganguli, T Namekawa, D Thaper, S Linder, ...
Nature cell biology 23 (9), 1023-1034, 2021
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐and CXCL8‐mediated cancer cell migration
B Cioni, E Nevedomskaya, MHM Melis, J van Burgsteden, S Stelloo, ...
Molecular oncology 12 (8), 1308-1323, 2018
Mandates: Dutch Cancer Society
Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations
S Schmid, A Omlin, C Higano, C Sweeney, NM Chanza, N Mehra, ...
JAMA network open 3 (10), e2021692-e2021692, 2020
Mandates: US National Institutes of Health
Androgen receptor profiling predicts prostate cancer outcome
S Stelloo, E Nevedomskaya, HG van der Poel, J de Jong, ...
EMBO molecular medicine 7 (11), 1450-1464, 2015
Mandates: Dutch Cancer Society
Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion
B Cioni, A Zaalberg, JR van Beijnum, MHM Melis, J van Burgsteden, ...
Nature communications 11 (1), 4498, 2020
Mandates: Dutch Cancer Society
The circadian cryptochrome, CRY1, is a pro-tumorigenic factor that rhythmically modulates DNA repair
AA Shafi, CM McNair, JJ McCann, M Alshalalfa, A Shostak, TM Severson, ...
Nature communications 12 (1), 401, 2021
Mandates: US National Institutes of Health, Dutch Cancer Society
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
S Linder, HG van der Poel, AM Bergman, W Zwart, S Prekovic
Endocrine-related cancer 26 (1), R31-R52, 2019
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
Cistrome partitioning reveals convergence of somatic mutations and risk variants on master transcription regulators in primary prostate tumors
P Mazrooei, KJ Kron, Y Zhu, S Zhou, G Grillo, T Mehdi, M Ahmed, ...
Cancer Cell 36 (6), 674-689. e6, 2019
Mandates: Canadian Cancer Society, Canadian Institutes of Health Research, Prostate …
Optimized ChIP-seq method facilitates transcription factor profiling in human tumors
AA Singh, K Schuurman, E Nevedomskaya, S Stelloo, S Linder, M Droog, ...
Life science alliance 2 (1), 2019
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer toward androgen independence
S Linder, M Hoogstraat, S Stelloo, N Eickhoff, K Schuurman, H de Barros, ...
Cancer discovery 12 (9), 2074-2097, 2022
Mandates: US Department of Defense, US National Institutes of Health, Netherlands …
Frequent clonal relations between metastases and non-index prostate cancer lesions
J Kneppers, O Krijgsman, M Melis, J de Jong, DS Peeper, E Bekers, ...
JCI insight 4 (2), 2019
Mandates: Netherlands Organisation for Scientific Research, Dutch Cancer Society
Publication and funding information is determined automatically by a computer program